JAGUAR HEALTH INC (JAGX) Stock Price & Overview
NASDAQ:JAGX • US47010C8881
The current stock price of JAGX is 0.503 USD. Today JAGX is down by -7.88%. In the past month the price decreased by -14.13%. In the past year, price decreased by -95.48%.
JAGX Key Statistics
- Market Cap
- 2.284M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -33.58
- Dividend Yield
- N/A
JAGX Stock Performance
JAGX Stock Chart
JAGX Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to JAGX. When comparing the yearly performance of all stocks, JAGX is a bad performer in the overall market: 98.85% of all stocks are doing better.
JAGX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to JAGX. JAGX has a bad profitability rating. Also its financial health evaluation is rather negative.
JAGX Earnings
On November 18, 2025 JAGX reported an EPS of -6.28 and a revenue of 3.08M. The company missed EPS expectations (-21.2% surprise) and missed revenue expectations (-18.98% surprise).
JAGX Forecast & Estimates
7 analysts have analysed JAGX and the average price target is 16.32 USD. This implies a price increase of 3144.53% is expected in the next year compared to the current price of 0.503.
For the next year, analysts expect an EPS growth of 89.56% and a revenue growth 24.03% for JAGX
JAGX Groups
Sector & Classification
JAGX Financial Highlights
Over the last trailing twelve months JAGX reported a non-GAAP Earnings per Share(EPS) of -33.58. The EPS decreased by -19.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -81.45% | ||
| ROE | -716.07% | ||
| Debt/Equity | 1.36 |
JAGX Ownership
JAGX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 28.18 | 921.899B | ||
| JNJ | JOHNSON & JOHNSON | 20.74 | 583.292B | ||
| MRK | MERCK & CO. INC. | 22.34 | 286.575B | ||
| PFE | PFIZER INC | 8.9 | 152.733B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.33 | 120.05B | ||
| ZTS | ZOETIS INC | 16.34 | 48.739B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.83 | 26.461B | ||
| VTRS | VIATRIS INC | 5.39 | 15.889B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.81 | 11.276B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.883B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.361B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.698B | ||
| LGND | LIGAND PHARMACEUTICALS | 23.9 | 4.217B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About JAGX
Company Profile
Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The company is headquartered in San Francisco, California and currently employs 49 full-time employees. The company went IPO on 2015-05-13. The firm is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. The company has an exclusive distribution agreement for the sale of Gelclair. The company is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.
Company Info
IPO: 2015-05-13
JAGUAR HEALTH INC
200 Pine Street Suite 400
San Francisco CALIFORNIA 94104 US
CEO: Lisa A. Conte
Employees: 49
Phone: 13026587581
JAGUAR HEALTH INC / JAGX FAQ
What does JAGX do?
Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The company is headquartered in San Francisco, California and currently employs 49 full-time employees. The company went IPO on 2015-05-13. The firm is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. The company has an exclusive distribution agreement for the sale of Gelclair. The company is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.
What is the stock price of JAGUAR HEALTH INC today?
The current stock price of JAGX is 0.503 USD. The price decreased by -7.88% in the last trading session.
Does JAGX stock pay dividends?
JAGX does not pay a dividend.
What is the ChartMill technical and fundamental rating of JAGX stock?
JAGX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is JAGUAR HEALTH INC (JAGX) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on JAGX.
Can you provide the upcoming earnings date for JAGUAR HEALTH INC?
JAGUAR HEALTH INC (JAGX) will report earnings on 2026-03-30, after the market close.
What is the Short Interest ratio of JAGUAR HEALTH INC (JAGX) stock?
The outstanding short interest for JAGUAR HEALTH INC (JAGX) is 15.44% of its float.